-
Company Insights
Innovation and Patenting activity of Laboratorios Farmaceuticos Rovi SA Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Laboratorios Farmaceuticos Rovi SA Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gebasaxturev in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gebasaxturev in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gebasaxturev in Hypopharyngeal Cancer Drug Details: Cavatak (Coxsackievirus A21, CVA-21) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Epcoritamab in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Epcoritamab in Burkitt Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Epcoritamab in Burkitt Lymphoma Drug Details: Epcoritamab-Bysp (Epkinly / Tepkinly) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Codeine + Dipyrone) in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Codeine + Dipyrone) in Post-Operative Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Codeine + Dipyrone) in Post-Operative Pain Drug Details: The fixed...
-
Product Insights
NewMacular Edema – Drugs In Development, 2024
Empower your strategies with our Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the...
-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...
-
Product Insights
NewLeiomyoma – Drugs In Development, 2024
Empower your strategies with our Leiomyoma – Drugs In Development, 2024 report and make more profitable business decisions. A leiomyoma, also known as a fibroid, is a benign smooth muscle tumor that very rarely becomes cancer. They can occur in any organ, but the most common forms occur in the uterus, small bowel, and the esophagus. It commonly affects individuals between menarche and menopause. The Leiomyoma drugs in development market research report provide comprehensive information on the therapeutics under development for...
-
Product Insights
NewNasopharyngitis (Common Cold) – Drugs In Development, 2024
Empower your strategies with our Nasopharyngitis (Common Cold) – Drugs In Development, 2024 report and make more profitable business decisions. Nasopharyngitis, also known as the common cold, is an infectious inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes, or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache, and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain...
-
Product Insights
NewVenous (Vein) Thrombosis – Drugs In Development, 2024
Empower your strategies with our Venous (Vein) Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions. Venous thromboembolism (VTE) is a condition characterized by the formation of blood clots in veins, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT typically manifests in deep veins, commonly in the lower leg, thigh, or pelvis, and can extend to the arms, particularly with intravenous central lines. Pulmonary embolism occurs when a detached clot travels to the lungs. With...